Companies › MacroGenics
5 active drug programs in 8 registered trials: 4 Phase 1, 4 Phase 2; Oncology, Gastroenterology; next expected readout Nov 2026.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| Lorigerlimab Bispecific DART protein binding PD-1 and CTLA-4 | PDCD1, CTLA4 | Phase 2 | Platinum-resistant Ovarian Cancer; Colorectal Cancer; Metastatic Cancer; Pancreatic Adenocarcinoma | Jul 2027 |
| MGC028 anti-ADAM9 antibody-drug conjugate | ADAM9 | Phase 1 | Advanced Solid Tumors | Nov 2026 |
| MGD024 CD123 x CD3 bispecific DART molecule | CD123, CD3 | Phase 1 | Leukemia, Acute Myeloid | Nov 2026 |
| MGC030 Antibody-drug conjugate | – | Phase 1 | Urothelial Cancer | Sep 2028 |
| vobramitamab tavatecan anti-TROP2 antibody-drug conjugate with SN-38 payload | TROP2 | Phase 1 | Advanced Solid Tumor | Oct 2028 |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT06723236 | MGC028 | Phase 1 | Advanced Solid Tumors | Oncology | Nov 2026 |
| NCT05362773 | MGD024 | Phase 1 | Leukemia, Acute Myeloid | Oncology | Nov 2026 |
| NCT07071961 | Lorigerlimab | Phase 2 | Colorectal Cancer | Oncology | May 2027 |
| NCT06730347 | Lorigerlimab | Phase 2 | Platinum-resistant Ovarian Cancer | Oncology | Jul 2027 |
| NCT05475171 | Lorigerlimab | Phase 2 | Metastatic Cancer | Oncology | Jun 2028 |
| NCT07822399 | MGC030 | Phase 1 | Urothelial Cancer | Gastroenterology | Sep 2028 |
| NCT06242470 | vobramitamab tavatecan | Phase 1 | Advanced Solid Tumor | Oncology | Oct 2028 |
| NCT07565155 | Lorigerlimab | Phase 2 | Pancreatic Adenocarcinoma | Oncology | Jan 2032 |
Cash of $114m on 2026-06-30; operating cash outflow about $155m a year; runway about 9 months at that burn, to Mar 2027; 0 of 4 coming phase 2-3 readouts fall inside that runway
Press releases filed as 8-K in the last year:
Held by 4 of the 39 life-science funds Phaseline follows through their 13F filings. Who holds what.
TScan Therapeutics Tyra Biosciences Agenus Xencor Shanghai Juncell Therapeutics
Pipelines of the same shape: areas, drug types, target families, stage and cash runway.
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.